South San Francisco startup Tenaya Therapeutics Inc. has ambitious plans to advance three drug development platforms for cardiovascular disease: cell therapy, gene therapy and small molecule precision medicine. After completing a rich series B round, which drew $92m in financing, the company says it has sufficient funding to move all three platforms toward the clinic.
"The $92m raise, it was large partly because we excited many investors who saw the potential of not one, not two, but three distinct platforms," CEO Faraz Ali said in an interview
